

The African Pharmacology Science Gateway (APSG)

Jaran Eriksen¹, Lars L Gustafsson¹, Simon Talyor², Amos Nungu³, Collen Masimerembwa⁴

1. Division of Clinical Pharmacology, Dept of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden
2. Department of Computer Sciences, Brunel University, London, United Kingdom
3. Dar es Salaam Institute of Technology, Tanzania
4. African Institute of Biomedical Science & Technology, Harare, Zimbabwe and chair of the APSG board



Sci-GaIA

Background

Many African scientists trained in high-income countries
Often technology transfer required for trained scientists to work at their African home institutions failed

Those who returned and remain in Africa have limited resources to maintain and develop strong research programs and institutions

A few African groups have established key research areas for drug development and Rational Use of Medicines. These groups are often scientifically isolated with few opportunities or possibilities for interaction to realize and build synergies from the knowledge and technical skills they have individually established


The African Pharmacology Science Gateway (APSG) was developed in response to needs and requirements defined by pharmacologists in Zimbabwe, South Africa, Ethiopia, Nigeria, Kenya, Tanzania, Uganda, focusing on the following areas :

1. Genomics and bioinformatics
2. Pharmacokinetics/pharmacometrics
3. Bioanalysis, drug analysis and metabolism
4. Clinical trial sciences

Aim

The APSG aims to significantly contribute towards simplifying collaboration and thereby help strengthening both capacity and capability for drug development and Rational Use of Medicines in Africa.

<http://sgw.africa-grid.org/pharmacology-science-gateway>



Conclusion

The APSG platform effectively enables north-south and south-south capacity and capability strengthening as African researchers and their international collaborators get an easily accessible arena of interaction.

What is the African Pharmacology Science Gateway?

- a virtual collaborative community linked to the African Grid Science Gateway.
- builds on easily accessible tools, preferably open access for affordability and sustainability.
- simplifies collaboration and sharing of resources in Africa
- should promote and implement African medical science collaboration focusing on:
 - a. biomedical and pharmacological sciences,
 - b. clinical trials and clinical drug studies for improving African healthcare.


Possible adaptation to needs for Medicines Utilization Research in Africa (MURIA) group – access to:

- Publishing drug utilization data
- Tools for data analysis (e.g. DDD, DU90)
- facilities for sharing data and discussing scientific and technical topics

Sci-GaIA (Energising Scientific Endeavour through Science Gateways and e-Infrastructures in Africa) proposes to produce clearly structured guides and educational documents that can be used to train and support representatives of National Research and Education Networks (NRENs), Communities of Practice (CoPs) and, importantly, Universities to develop Science Gateways and e-Infrastructures in Africa. This will give a sustainable foundation on which African e-Infrastructures can be developed. Importantly, the results of Sci-GaIA will be usable by CoPs in Europe and the rest of the world.

The APSG is for you!

The APSG is the first Science Gateway in the Sci-GaIA project and we would like to see you use it. Help us improve it by testing it and giving feedback and suggestions. Join us on discourse.sci-gaia.eu and feel free to contact us on www.sci-gaia.eu or jaran.eriksen@ki.se



Jaran Eriksen, MD PhD
Division of Clinical Pharmacology, Department of Laboratory Sciences
Karolinska Institutet at Karolinska University Hospital
C1 68 Karolinska University Hospital Huddinge
141 86 Stockholm, Sweden
E-mail: jaran.eriksen@ki.se www.ki.se or www.karolinska.se



**Karolinska
Institutet**



Sci-GaIA
Energising Scientific Endeavour through Science Gateways
and e-Infrastructures in Africa

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement n°654237

